OBJECTIVE: APOE ε4 status has been associated with greater cortical amyloid deposition, whereas exercise has been associated with less in cognitively normal adults. The primary objective here was to examine whether physical exercise moderates the association between APOE genotype and amyloid deposition in cognitively normal adults. DESIGN: APOE genotyping data and answers to a questionnaire on physical exercise engagement over the last decade were obtained in conjunction with cerebrospinal fluid (CSF) samples and amyloid imaging with carbon 11-labeled Pittsburgh Compound B ([(11)C]PiB) positron emission tomography. Participants were classified as either low or high exercisers based on exercise guidelines of the American Heart Association. SETTING: Knight Alzheimer's Disease Research Center at Washington University, St Louis, Missouri. PARTICIPANTS: A total of 201 cognitively normal adults (135 of whom were women) aged 45 to 88 years were recruited from the Knight Alzheimer's Disease Research Center. Samples of CSF were collected from 165 participants. Amyloid imaging was performed for 163 participants. RESULTS: APOE ε4 carriers evidenced higher [(11)C]PiB binding (P<.001) and lower CSF Aβ42 levels (P<.001) than did noncarriers. Our previous findings of higher [(11)C]PiB binding (P=.005) and lower CSF Aβ42 levels (P=.009) in more sedentary individuals were replicated. Most importantly, we observed a novel interaction between APOE status and exercise engagement for [(11)C]PiB binding (P=.008) such that a more sedentary lifestyle was significantly associated with higher [(11)C]PiB binding for ε4 carriers (P=.013) but not for noncarriers (P=.20). All findings remained significant after controlling for age; sex; educational level; body mass index; the presence or history of hypertension, diabetes mellitus, heart problems, or depression; and the interval between assessments. CONCLUSION: Collectively, these results suggest that cognitively normal sedentary APOE ε4-positive individuals may be at augmented risk for cerebral amyloid deposition.
OBJECTIVE:APOE ε4 status has been associated with greater cortical amyloid deposition, whereas exercise has been associated with less in cognitively normal adults. The primary objective here was to examine whether physical exercise moderates the association between APOE genotype and amyloid deposition in cognitively normal adults. DESIGN:APOE genotyping data and answers to a questionnaire on physical exercise engagement over the last decade were obtained in conjunction with cerebrospinal fluid (CSF) samples and amyloid imaging with carbon 11-labeled Pittsburgh Compound B ([(11)C]PiB) positron emission tomography. Participants were classified as either low or high exercisers based on exercise guidelines of the American Heart Association. SETTING: Knight Alzheimer's Disease Research Center at Washington University, St Louis, Missouri. PARTICIPANTS: A total of 201 cognitively normal adults (135 of whom were women) aged 45 to 88 years were recruited from the Knight Alzheimer's Disease Research Center. Samples of CSF were collected from 165 participants. Amyloid imaging was performed for 163 participants. RESULTS:APOE ε4 carriers evidenced higher [(11)C]PiB binding (P<.001) and lower CSF Aβ42 levels (P<.001) than did noncarriers. Our previous findings of higher [(11)C]PiB binding (P=.005) and lower CSF Aβ42 levels (P=.009) in more sedentary individuals were replicated. Most importantly, we observed a novel interaction between APOE status and exercise engagement for [(11)C]PiB binding (P=.008) such that a more sedentary lifestyle was significantly associated with higher [(11)C]PiB binding for ε4 carriers (P=.013) but not for noncarriers (P=.20). All findings remained significant after controlling for age; sex; educational level; body mass index; the presence or history of hypertension, diabetes mellitus, heart problems, or depression; and the interval between assessments. CONCLUSION: Collectively, these results suggest that cognitively normal sedentary APOE ε4-positive individuals may be at augmented risk for cerebral amyloid deposition.
Authors: Brenda L Plassman; John W Williams; James R Burke; Tracey Holsinger; Sophiya Benjamin Journal: Ann Intern Med Date: 2010-06-14 Impact factor: 25.391
Authors: Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman Journal: Ann Neurol Date: 2009-02 Impact factor: 10.422
Authors: Sean P Deeny; David Poeppel; Jo B Zimmerman; Stephen M Roth; Josef Brandauer; Sarah Witkowski; Joseph W Hearn; Andrew T Ludlow; José L Contreras-Vidal; Jason Brandt; Bradley D Hatfield Journal: Biol Psychol Date: 2008-03-02 Impact factor: 3.251
Authors: Kelvin Y Liang; Mark A Mintun; Anne M Fagan; Alison M Goate; Julie M Bugg; David M Holtzman; John C Morris; Denise Head Journal: Ann Neurol Date: 2010-09 Impact factor: 10.422
Authors: Richard J Caselli; Amylou C Dueck; David Osborne; Marwan N Sabbagh; Donald J Connor; Geoffrey L Ahern; Leslie C Baxter; Steven Z Rapcsak; Jiong Shi; Bryan K Woodruff; Dona E C Locke; Charlene Hoffman Snyder; Gene E Alexander; Rosa Rademakers; Eric M Reiman Journal: N Engl J Med Date: 2009-07-16 Impact factor: 91.245
Authors: Joan Lindsay; Danielle Laurin; René Verreault; Réjean Hébert; Barbara Helliwell; Gerry B Hill; Ian McDowell Journal: Am J Epidemiol Date: 2002-09-01 Impact factor: 4.897
Authors: L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn Journal: JAMA Date: 1997 Oct 22-29 Impact factor: 56.272
Authors: Bruce W Patterson; Donald L Elbert; Kwasi G Mawuenyega; Tom Kasten; Vitaliy Ovod; Shengmei Ma; Chengjie Xiong; Robert Chott; Kevin Yarasheski; Wendy Sigurdson; Lily Zhang; Alison Goate; Tammie Benzinger; John C Morris; David Holtzman; Randall J Bateman Journal: Ann Neurol Date: 2015-07-20 Impact factor: 10.422
Authors: C A Raji; H Eyre; S H Wei; D E Bredesen; S Moylan; M Law; G Small; P M Thompson; R M Friedlander; D H Silverman; B T Baune; T A Hoang; N Salamon; A W Toga; M W Vernooij Journal: AJNR Am J Neuroradiol Date: 2015-06-04 Impact factor: 3.825
Authors: Christopher M Gidicsin; Jacqueline E Maye; Joseph J Locascio; Lesley C Pepin; Marlie Philiossaint; J Alex Becker; Alayna P Younger; Maria Dekhtyar; Aaron P Schultz; Rebecca E Amariglio; Gad A Marshall; Dorene M Rentz; Trey Hedden; Reisa A Sperling; Keith A Johnson Journal: Neurology Date: 2015-06-10 Impact factor: 9.910
Authors: Michelle W Voss; Carmen Soto; Seungwoo Yoo; Matthew Sodoma; Carmen Vivar; Henriette van Praag Journal: Trends Cogn Sci Date: 2019-02-16 Impact factor: 20.229
Authors: Donald M Lyall; Carlos Celis-Morales; Laura M Lyall; Christopher Graham; Nicholas Graham; Daniel F Mackay; Rona J Strawbridge; Joey Ward; Jason M R Gill; Naveed Sattar; Jonathan Cavanagh; Daniel J Smith; Jill P Pell Journal: Neurology Date: 2019-04-26 Impact factor: 9.910